Skip to Content

Join the 'Efavirenz' group to help and get support from people like you.

Efavirenz News

HIV Cells Keep Duplicating Even When Treatments Are Working: Study

Posted 6 Aug 2015 by Drugs.com

THURSDAY, Aug. 6, 2015 – HIV can continue to multiply in patients who are responding well to antiretroviral therapy, U.K. researchers say. Treatment advances over the last 30 years mean that HIV – the virus that causes AIDS – is suppressed to almost undetectable levels in many patients, and they can live a long and healthy life. It was believed that after many years of successful therapy, a patient's body would naturally rid itself of HIV. "This research shows that sadly, the HIV virus has found yet another way to escape our treatments," study leader Anna Maria Geretti, a professor from the University of Liverpool in the United Kingdom, said in a university news release. During treatment, the virus tries to avoid destruction by hiding in blood cells that trigger an immune response. HIV does this by integrating its own genetic information into the DNA of immune system cells called CD4 ... Read more

Related support groups: HIV Infection, Incivek, Pre-Exposure Prophylaxis, Baraclude, Victrelis, Tenofovir, Viread, Kaletra, Norvir, Entecavir, Telaprevir, Lamivudine, Diagnosis and Investigation, Boceprevir, Lexiva, Efavirenz, Nevirapine, Ritonavir, Reyataz, Olysio

Many U.S. AIDS Patients Still Die When 'Opportunistic' Infections Strike

Posted 1 Jul 2015 by Drugs.com

WEDNESDAY, July 1, 2015 – Even after the advent of powerful medications for suppressing HIV, a new study finds that more than one-third of people in San Francisco who were diagnosed with an AIDS-related infection died within five years. "The main cause of mortality arises from people stopping treatment entirely," said Dr. Robert Grant, a professor at the University of California, San Francisco, who reviewed the findings but was not involved in the research. When HIV treatment lapses, so-called "opportunistic" infections and illnesses can arise, posing a real threat to patients' health, he explained. The bottom line, according to Grant, is that there is still "a long way to go" in prolonging the lives of Americans with HIV/AIDS. The new study was led by Dr. Sandra Schwarcz, associate professor of epidemiology and biostatistics at the University of California, San Francisco. She and her ... Read more

Related support groups: Harvoni, HIV Infection, Tamiflu, Atripla, Sovaldi, Incivek, Pre-Exposure Prophylaxis, Truvada, Baraclude, Mycobacterium avium-intracellulare, Stribild, Victrelis, Mycobacterium avium-intracellulare - Treatment, Complera, Tenofovir, Kaletra, Oseltamivir, Viread, Entecavir, Sofosbuvir

Sequence of Shots May Lead to Effective HIV Vaccine, Mouse Study Finds

Posted 25 Jun 2015 by Drugs.com

THURSDAY, June 25, 2015 – It's unlikely that a single vaccine would ever enable the body to neutralize the HIV virus, but a sequence of immunizations might hold the key, a new mouse study suggests. The immune system could be guided in a series of steps to develop a special type of HIV-fighting antibody, a team of researchers said. Each immunization would be customized for specific stages of the immune system's response to the virus. In the end, the series of shots would result in the production of broadly neutralizing antibodies capable of fighting HIV, the authors said. "As HIV mutates in a patient, the immune system continually adapts. In some patients, this process produces broadly neutralizing antibodies, which are unusual antibodies that can bind to and neutralize a wide range of globally occurring HIV variants. These are the antibodies we want to try to elicit with a vaccine," ... Read more

Related support groups: Harvoni, HIV Infection, Atripla, Sovaldi, Incivek, Pre-Exposure Prophylaxis, Truvada, Baraclude, Stribild, Victrelis, Complera, Tenofovir, Kaletra, Viread, Sofosbuvir, Entecavir, Norvir, Telaprevir, Triumeq, Lamivudine

1 in 5 Younger Americans Tested for HIV

Posted 2 Jun 2015 by Drugs.com

TUESDAY, June 2, 2015 – Nearly one-fifth of teens and younger adults in the United States have been tested recently for HIV, federal health officials reported Tuesday. In 2011, more than 1 million Americans 13 and older had HIV, but one in seven did not know their infection status. Routine, voluntary testing is known to reduce transmission of HIV, the virus that causes AIDS, according to the U.S. Centers for Disease Control and Prevention. Researchers at the CDC's National Center for Health Statistics analyzed data from 5,600 females and more than 4,800 males, ages 15-44, who took part in the 2011-2013 National Survey of Family Growth. The researchers found that 19 percent had undergone HIV testing in the past year, an increase from 17 percent in both 2002 and 2006-2010. HIV testing rates in 2011-2013 were 22 percent for females and 16 percent for males, compared with 20 percent for ... Read more

Related support groups: Harvoni, HIV Infection, Atripla, Incivek, Pre-Exposure Prophylaxis, Truvada, Baraclude, Stribild, Victrelis, Complera, Tenofovir, Kaletra, Viread, Entecavir, Norvir, Triumeq, Telaprevir, Lamivudine, Diagnosis and Investigation, Olysio

Global Trial Finds HIV Drugs Should Be Taken Right After Diagnosis

Posted 28 May 2015 by Drugs.com

WEDNESDAY, May 27, 2015 – People with HIV should start taking medications to battle the virus that causes AIDS as soon as they're diagnosed, a new international study finds. Scientists involved in the trial were so impressed by the health benefits of early use of HIV drugs that they shut the study down early so they could offer the medications to all participants. The findings could alter World Health Organization guidelines about the best way to treat people with HIV, experts said. Currently, WHO recommends that HIV patients not start treatment until their immune system show signs of weakening. "We now have clear-cut proof that it is of significantly greater health benefit to an HIV-infected person to start antiretroviral therapy sooner rather than later," Dr. Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases, said in a statement. "Moreover, ... Read more

Related support groups: Harvoni, HIV Infection, Tamiflu, Atripla, Incivek, Truvada, Baraclude, Stribild, Victrelis, Complera, Tenofovir, Oseltamivir, Kaletra, Viread, Norvir, Entecavir, Telaprevir, Triumeq, Lamivudine, Nevirapine

Experimental AIDS Vaccine Targets Hidden Virus

Posted 29 Apr 2015 by Drugs.com

WEDNESDAY, April 29, 2015 – Preliminary research suggests that an AIDS vaccine in development can ramp up the body's immune system, boosting the response to medications HIV-positive patients take. Years of research will be required to confirm that the vaccine works, and researchers don't yet have the major funding needed to continue and push the experimental vaccine toward the market. Still, there's tremendous potential, said study senior author Dr. Barbara Ensoli, director of the National AIDS Center at the National Institute of Health in Rome, Italy. "Although the results are from infected patients, the vaccine may be suitable for both healthy and HIV-infected patients," said Ensoli. So far, she said, the vaccine appears to be well tolerated, with no signs of significant side effects. A vaccine has long been the holy grail of research into AIDS and HIV, the virus that causes the ... Read more

Related support groups: Harvoni, HIV Infection, Atripla, Incivek, Truvada, Baraclude, Stribild, Victrelis, Complera, Tenofovir, Kaletra, Viread, Entecavir, Norvir, Telaprevir, Triumeq, Lamivudine, Reyataz, Efavirenz, Lexiva

Study: Common HIV Drug May Boost Suicide Risk

Posted 30 Jun 2014 by Drugs.com

MONDAY, June 30, 2014 – A medication commonly used to treat HIV appears to double the risk that patients will develop suicidal thoughts or take their lives, new research contends. The finding concerns the anti-HIV drug efavirenz, which is marketed as Sustiva. Prior investigations indicated that efavirenz might boost suicide risk because of a negative impact on the central nervous system. The new investigation is the first to pinpoint a link to suicidal thoughts, attempts and completion, the researchers said. "Efavirenz is a very important and effective antiretroviral medication that is the foundation for much of HIV therapy worldwide," said study co-author Dr. Joseph Eron, of the University of North Carolina Center for AIDS Research at Chapel Hill. "Our study demonstrated a clear association between efavirenz and suicidality," he said. Although that risk seems very small, he said, it ... Read more

Related support groups: HIV Infection, Atripla, Efavirenz, Sustiva, Efavirenz/Emtricitabine/Tenofovir

Kids More Likely Than Adults To Be Resistant to HIV Meds: Study

Posted 27 May 2014 by Drugs.com

TUESDAY, May 27, 2014 – Children born with HIV face a greater risk of developing resistance to life-saving antiretroviral drugs than HIV-infected adults do, according to new research. Antiretroviral drugs are used to treat people infected with HIV, the virus that causes AIDS. "The problem with drug resistance is that once you develop it, it never goes away," study author Dr. Russell Van Dyke, a professor of pediatric infectious diseases at Tulane University School of Medicine, said in a university news release. "Some patients with very resistant virus have no effective treatment options. Resistant virus is the major reason for death among youth" who were born with HIV, he added. The study looked at 450 HIV-infected children across the United States and found that 74 percent were resistant to at least one type of HIV drug, and 30 percent were resistant to two classes of drugs. By ... Read more

Related support groups: HIV Infection, Sovaldi, Incivek, Baraclude, Victrelis, Tenofovir, Kaletra, Viread, Sofosbuvir, Norvir, Entecavir, Telaprevir, Lamivudine, Ritonavir, Reyataz, Efavirenz, Nevirapine, Olysio, Boceprevir, Lexiva

Bristol-Myers Squibb Receives US FDA sNDA Approval for Use of Sustiva (efavirenz) in HIV-1 Infected Pediatric Patients

Posted 6 May 2013 by Drugs.com

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for Sustiva (efavirenz), including dosing recommendations for HIV-1 infected pediatric patients three months to three years old and weighing at least 3.5 kg. This approval offers a once-daily option as part of a regimen for this population and includes a “capsule sprinkle” administration method for patients who cannot swallow capsules or tablets. Detailed information about the “capsule sprinkle” method is provided in the ‘Instructions for Use’ at the end of the Patient Information section of the Package Insert. Sustiva is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that was originally approved in the U.S. in 1998 to treat HIV-1 infected children three years of age or older and weighing at least ... Read more

Related support groups: HIV Infection, Efavirenz, Sustiva

Researchers Describe First 'Functional Cure' of HIV in Baby

Posted 4 Mar 2013 by Drugs.com

SUNDAY, March 3 – A baby born two-and-a-half years ago in Mississippi with HIV is the first case of a so-called "functional cure" of the infection, researchers announced Sunday. Standard tests can no longer detect any traces of the AIDS-causing virus even though the child has discontinued HIV medication. "We believe this is the first well-documented case of a [functional] cure," said study lead author Dr. Deborah Persaud, associate professor of pediatrics in the division of infectious diseases at Johns Hopkins Children's Center in Baltimore. The finding was presented Sunday at the Conference on Retroviruses and Opportunistic Infections, in Atlanta. The child was not part of a study but, instead, the beneficiary of an unexpected and partly unplanned sequence of events that – once confirmed and replicated in a formal study – might help more children who are born with HIV or who at risk ... Read more

Related support groups: HIV Infection, Incivek, Baraclude, Victrelis, Tenofovir, Viread, Kaletra, Norvir, Entecavir, Telaprevir, Lamivudine, Efavirenz, Nevirapine, Ritonavir, Lexiva, Boceprevir, Reyataz, Hepsera, Prezista, Epivir

HIV Drug Combo May Help Prevent Malaria Reinfection

Posted 29 Nov 2012 by Drugs.com

WEDNESDAY, Nov. 28 – Treatment with a combination of certain HIV drugs greatly reduces the risk of recurrent malaria in children with HIV who are also being treated with drugs to prevent the mosquito-borne infection, according to new research. The study included more than 170 HIV-positive infants and children up to 6 years old in Uganda who were receiving anti-malarial drugs and HIV treatment, including either a combination of the protease inhibitors lopinavir and ritonavir, or a class of drugs called non-nucleoside reverse transcriptase inhibitors (NNRTIs). Despite the anti-malarial drugs and other preventive measures – such as mosquito nets – the children's risk of developing malaria during their first six months of HIV treatment was more than 40 percent. The risk during that time period was about the same whether the children were taking the protease inhibitors or an NNRTI, the ... Read more

Related support groups: HIV Infection, Malaria, Incivek, Malaria Prevention, Victrelis, Kaletra, Norvir, Telaprevir, Malaria Prophylaxis, Ritonavir, Efavirenz, Boceprevir, Reyataz, Nevirapine, Lexiva, Prezista, Norvir Soft Gelatin, Agenerase, Indinavir, Intelence

FDA: More Than 150 Antiretroviral Drugs Available Through PEPFAR for Worldwide HIV/AIDS Relief

Posted 23 Jul 2012 by Drugs.com

July 23, 2012 – Today, U.S. Food and Drug Administration (FDA) Commissioner Margaret A. Hamburg announced the agency has approved or tentatively approved a total of 152 antiretroviral drugs in association with the President’s Emergency Plan for AIDS Relief (PEPFAR) to treat those infected with HIV/AIDS in countries that lack the tools needed to fight the AIDS epidemic. The most recent FDA actions in association with PEPFAR were tentative approvals of the following generic drugs: abacavir oral solution (Hetero Labs Ltd. Unit III, July 2, 2012) lopinavir and ritonavir oral solution (Cipla Ltd., June 29, 2012) efavirenz tablets (Edict Pharmaceuticals Private Ltd., June 25, 2012 and Micro Labs Ltd., June 20, 2012) Tentative approval means that although FDA has found that a drug product has met all required manufacturing quality, clinical safety, and efficacy requirements, it cannot be a ... Read more

Related support groups: HIV Infection, Atripla, Incivek, Baraclude, Victrelis, Tenofovir, Kaletra, Viread, Norvir, Entecavir, Telaprevir, Lamivudine, Nevirapine, Lexiva, Ritonavir, Boceprevir, Efavirenz, Reyataz, Hepsera, Prezista

All HIV Patients Should Take Meds Early On, Experts Now Say

Posted 23 Jul 2012 by Drugs.com

MONDAY, July 23 – A new report recommends that physicians begin treating all HIV-positive adults with antiretroviral drugs instead of waiting, at least in countries where the therapy is easily accessible. All HIV-positive patients should take the drugs, even if blood tests reveal that their immune system is healthy, according to the revised guidelines, which were presented Sunday at the International AIDS Conference in Washington D.C., and published in the July 25 issue of the Journal of the American Medical Association. Over the last 25 years, antiretroviral drugs have become stronger, easier to tolerate and simpler to take, the authors of the report explained. "New trial data and drug regimens that have become available in the last two years warrant an update to guidelines for antiretroviral therapy in HIV-infected adults in resource-rich settings," Dr. Melanie Thompson and her 2012 ... Read more

Related support groups: HIV Infection, Incivek, Baraclude, Victrelis, Tenofovir, Viread, Kaletra, Norvir, Entecavir, Telaprevir, Lamivudine, Efavirenz, Nevirapine, Ritonavir, Lexiva, Boceprevir, Reyataz, Hepsera, Prezista, Epivir

Studies Show Value of AIDS Drugs as Prevention

Posted 11 Jul 2012 by Drugs.com

WEDNESDAY, July 11 – Researchers have released the final results of two studies that suggest AIDS drugs can prevent exposed people in Africa from getting infected with HIV by their sexual partners. However, another study indicates that it's a tough job to convince African women who aren't at the highest risk to take preventive medications. In the big picture, the studies show that "we have a new HIV-prevention strategy, one that's quite powerful but also depends on adherence," said Dr. Jared Baeten, an associate professor of global health at the University of Washington, in Seattle. "The next step is figuring out how to motivate people to take it." The studies appeared online July 11 in the New England Journal of Medicine. The general findings of the studies have been previously released, but only now has the research become available in a medical journal after going through a ... Read more

Related support groups: HIV Infection, Incivek, Baraclude, Victrelis, Tenofovir, Viread, Kaletra, Norvir, Entecavir, Telaprevir, Lamivudine, Efavirenz, Nevirapine, Ritonavir, Lexiva, Boceprevir, Reyataz, Hepsera, Prezista, Epivir

Young Men Taking HIV Meds May Be at Risk for Bone Loss

Posted 22 Jun 2012 by Drugs.com

FRIDAY, June 22 – Young men receiving drug treatment for HIV infection are at increased risk for low bone mass, a new study suggests. The findings indicate that these patients should exercise, take vitamin D and be closely monitored in order to reduce their future risk of bone fractures, according to the study, released online in advance of print publication in the journal Clinical Infectious Diseases. The study included about 250 male participants, aged 14 to 25, who underwent whole-body scans to measure their bone density. Some of the men were infected with HIV, the virus that causes AIDS. The participants with HIV had been diagnosed with the infection an average of two years earlier. The HIV-infected males had an average 5 percent to 8 percent lower bone density in the hip and 2 percent to 4 percent lower bone density in the spine than those without HIV. Although the study uncovered ... Read more

Related support groups: HIV Infection, Incivek, Baraclude, Victrelis, Tenofovir, Viread, Kaletra, Norvir, Entecavir, Telaprevir, Lamivudine, Efavirenz, Nevirapine, Ritonavir, Lexiva, Boceprevir, Reyataz, Hepsera, Prezista, Epivir

Page 1 2 Next

Ask a Question

Further Information

Related Condition Support Groups

HIV Infection, Occupational Exposure, Nonoccupational Exposure

Related Drug Support Groups

Sustiva

Efavirenz Patient Information at Drugs.com